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ORIGINAL ARTICLE
Background: The proportion of patients with non–small-cell lung 
cancer (NSCLC) who undergo surgery with curative intent is one 
measure of effectiveness in treating lung cancer. To the best of our 
knowledge, surgical resection rate (SRR) for a whole nation has 
never been reported before. We studied the SRR and surgical out-
come of NSCLC patients in Iceland during a recent 15-year period.
Methods: This was a retrospective study of all pulmonary resections 
performed with curative intent for NSCLC in Iceland from 1994 
to 2008. Information was retrieved from medical records and from 
the Icelandic Cancer Registry. Patient demographics, postoperative 
tumor, node, metastasis stage, overall survival, and complication 
rates were compared over three 5-year periods.
Results: Of 1530 confirmed cases of NSCLC, 404 were resected, 
giving an SRR of 26.4%, which did not change significantly during 
the study period. Minor and major complication rates were 37.4% 
and 8.7%, respectively. Operative mortality rates were 0.7% for 
lobectomy, 3.3% for pneumonectomy, and 0% for lesser resection. 
Five-year survival after all procedures was 40.7% and improved from 
the first to the last 5-year period (34.8% versus 43.8%, p = 0.04). 
Five-year survival for stages I and II together was 46.8%, with no 
significant change in stage distribution between periods. Five-year 
survival after pneumonectomy was 22.0%, which was significantly 
lower than for lobectomy (44.6%) and lesser resection (40.7%) (p < 
0.005). Unoperated patients had a 5-year survival of 4.8%, as com-
pared to 12.4% for all the NSCLC patients together.
Conclusion: Compared with most other published studies, the SRR 
of NSCLC in Iceland is high. Short-term outcome is good, with a low 
rate of major complications and an operative mortality of only 1.0%. 
Five-year survival improved significantly over the study period.
Key Words: NSCLC, Resection rate, Outcome, Complications, Survival.
(J Thorac Oncol. 2012;7: 1164–1169)
Lung cancer is the leading cause of cancer-related deaths in the western world.1 In Iceland, the mortality from lung can-
cer is similar to that of breast, prostate, and colon cancer com-
bined, and non–small-cell lung cancer (NSCLC) accounts for 
about 85% of lung cancer cases.2 Although surgical resection 
is still the only well-defined curative treatment for NSCLC, 
it is only possible for the one third of patients diagnosed with 
stage I or stage II disease and for selected cases of stage IIIA 
disease.3,4,5
Surgical resection rate (SRR) is one measure of effec-
tiveness in treating NSCLC, for example, in a particular geo-
graphic location. SRR has varied considerably, often ranging 
from 15% to 25% in European studies,6–9 and it was 29% in a 
study including more than 700 hospitals in the United States.5 
However, smaller single-institution studies from the United 
States have found SRRs of up to 37%,10 and there have been 
studies from Europe that show SRRs as low as 10%.6,11–13 None 
of the previously published studies have found an SRR for a 
whole nation. The same applies to outcome analysis of sur-
gical treatment of NSCLC. Numerous authors have reported 
short-term complications and long-term survival for lobec-
tomies, pneumonectomies, and lesser resections separately, 
with only a few of the studies analyzing all the different pro-
cedures together. In these studies, the combined rate of major 
complications has been around or over 10%,14–16 and operative 
mortality has ranged from 1.5% to 7%.5,8,14,17–19 For pneumo-
nectomies, the figures were often double these values.14–16
The aim of this study was to investigate the SRR for 
the whole nation of Iceland using centralized databases in the 
country. Another aim was to determine surgical outcomes for 
the different lung procedures that were performed with cura-
tive intent in NSCLC patients in Iceland as a whole.
MATERIALS AND METHODS
This was a retrospective study of all patients in Iceland 
who underwent pulmonary resection with curative intent 
for NSCLC from January 1, 1994 to December 31, 2008. 
Exploratory-only thoracotomies, palliative procedures, and 
lesser resections for biopsy purposes were excluded.
A central, computerized histology database from the 
Department of Pathology of Landspitali University Hospital, 
containing details of all lung histology specimens in Iceland 
was used to identify cases. To minimize the risk of cases being 
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missed, we also reviewed the diagnosis and operation registry 
at Landspitali University Hospital, the only center performing 
cardiothoracic surgery in Iceland.
We obtained information on all cases with a histo-
logically confirmed diagnosis of primary NSCLC from the 
Icelandic Cancer Registry.2 This registry covers all cancer 
cases diagnosed at hospitals and other healthcare facilities 
in Iceland since 1955. SRR was calculated by dividing the 
number of all pulmonary resections with curative intent for 
NSCLC by the number of all histologically confirmed cases 
of NSCLC within the same period. One hundred and thirty-
three patients (6.6% of all patients with a lung cancer diag-
nosis) did not have a histologically confirmed diagnosis, and 
306 patients had small-cell carcinoma. These two groups were 
excluded from the NSCLC group that made up the denomina-
tor for the calculation of SRR. We also excluded patients with 
carcinoid tumors (n = 38), sarcomas, and carcinoma in situ.
Baseline demographic information and clinical data 
were collected from hospital charts and surgical reports using 
a standardized data sheet. Age, comorbidities, and presenting 
symptoms were collected along with data regarding the type 
of operation, tumor, postoperative tumor, node, metastasis 
(TNM) stage, complications, and survival.
Patients being considered for pulmonary resection had 
been reviewed by a multidisciplinary tumor board including 
thoracic surgeons, pulmonologists, oncologists, radiologists, 
and pathologists. The preoperative workup varied between 
patients, but usually included a chest radiograph, a computed 
tomography (CT) scan of the chest, upper abdomen and head, 
and also bone scintigraphy and spirometry. Preoperative biop-
sies were obtained through bronchoscopy or transthoracic 
CT-guided needle biopsy. Mediastinoscopy was performed pre-
operatively in a proportion of the cases, but positron emission 
tomography (PET) scan has never been available in Iceland.
Patients were staged postoperatively (pathological stage, 
pTNM) using both the 6th and the 7th edition of the TNM 
staging system,20 but data is primarily reported for the 6th ver-
sion. Preoperative clinical staging (cTNM) was not performed 
uniformly and is not reported in this study.
All surgical procedures were performed in general 
anesthesia with double lumen intubation and thoracic epidu-
ral anesthesia. The operations were performed by six surgeons 
using standardized techniques with intraoperative lymph-
adenectomy of enlarged hilar or ipsilateral mediastinal lymph 
nodes, but during the last 5-year period these lymph nodes 
were routinely removed or sampled. A posterolateral thora-
cotomy was most often performed, but during the last 5-year 
period an anterolateral approach was used.
Major complications were defined as reoperation for 
bleeding, heart failure, acute respiratory distress syndrome, 
myocardial infarction, empyema, stroke, and bronchopleu-
ral fistula. Minor complications were defined as air leakage 
for more than 7 days, pneumonia, intraoperative bleeding of 
more than 1 liter, atrial fibrillation/flutter, wound infection, 
and recurrent laryngeal nerve paralysis. Operative mortality 
was defined as death occurring within 30 days of surgery. To 
assess trends, the 15-year study period was divided into three 
5-year periods.
Statistics
Microsoft Excel was used for descriptive statistics, 
and R version 2.10.1 for survival calculations. Student’s t 
test, Fisher’s exact test, and the χ2 test were used to compare 
groups, and differences were considered to be statistically sig-
nificant when the p value was less than 0.05. Overall survival 
(OS) was analyzed by the Kaplan-Meier method, and the log-
rank test was used to compare survival between groups. All 
patients were followed up with respect to survival by using 
data from the Icelandic National Population Registry.21 In this 
way, patients could be assigned a date of death or were identi-
fied as living on July 10, 2010. Mean follow-up time was 49 
months (range, 0–194 months).
The study was approved by the Icelandic National Bioethics 
Committee and the Data Protection Authority. As individual 
patients were not identified, individual consent was waived.
RESULTS
There were 1530 histologically confirmed cases of 
NSCLC during the 15-year period, of which 404 underwent 
surgery (397 patients). The SRR was 26.4% and did not 
change significantly between the three 5-year periods (28.2%, 
24.3%, and 26.8%, respectively; Table 1). The surgical proce-
dures consisted of 297 lobectomies (73.5%), 60 pneumonec-
tomies (14.9%), and 47 lesser resections (11.6%).
The mean age of patients who underwent surgery was 
65.9 years; those in the pneumonectomy group were 6 years 
younger on average than those in the lesser resection group 
(Table 2). Over 95% of the patients were current or previous 
smokers, and many of them had reduced pulmonary function. 
A history of coronary artery disease and chronic obstructive 
TABLE 1.  Evaluation of Trends From 1994 to 2008 for 
Patients in Iceland Who Underwent Surgical Resection 
With Curative Intent for NSCLC, Divided into Three 5-Year 
Periods
1994–1998 
(n = 124)
1999–2003 
(n = 119)
2004–2008 
(n = 161)
All Periods 
(n = 404)
Male sex 66 (53.2) 60 (50.4) 85 (52.8) 211 (52.2)
Mean age 64.4 65.4 67.1 65.8
Age > 69 years 46 (37.1) 48 (40.3) 74 (46.0) 168 (41.6)
Surgical resection 
rate (SRR), %
28.2 24.3 26.8 26.4
Adenocarcinoma 
histology
67 (54.0) 64 (53.8) 103 (64.0) 234 (57.4)
Incidental 
diagnosis
40 (32.8) 38 (31.9) 61 (37.9) 139 (34.6)
Mediastinoscopy 
performed
11 (8.9) 21 (17.6) 25 (15.5) 57 (14.1)
Stage I or II 
disease
98 (79.0) 94 (79.0) 126 (7.83) 318 (78.7)
Pneumonectomies 16 (12.9) 18 (15.1) 26 (16.1) 60 (14.9)
5-year survival, % 34.8 40.6 43.8a 40.7
The numbers of patients are given with percentages in parentheses, except for age, 
surgical resection rate, and survival, where mean and percentage are given.
aStatistically significant difference between groups (p < 0.05).
NSCLC, non–small-cell lung cancer.
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pulmonary disease was significantly more common in patients 
who underwent lesser resection than in patients who underwent 
pneumonectomy or lobectomy. A forced expiratory volume of 
less than 75% of the predicted value in 1 second was also iden-
tified in more patients who underwent lesser resection (42.6% 
versus 28.9% for the other patients, p = 0.06; Table 2).
Adenocarcinoma was the most common histological 
type of lung cancer (57.4%), whereas squamous-cell histol-
ogy accounted for 31.7% (Table 3). Squamous-cell carcinoma 
was more frequent in those who underwent pneumonectomy 
than in the other patients. As shown in Table 3, almost 87% 
of the patients had stage I, stage II, or stage IIIA disease, 
but 13.9% had stage IIIB or IV disease in postoperative 
staging. The proportion of stage I cases was highest in the 
patients who underwent lesser resection (78.7%). In Table 
4 the stage distribution using the 7th edition of the TNM 
system is also given. The stage distribution did not change 
significantly between periods (Table 1). A mediastinoscopy 
was performed preoperatively in 20 of the pneumonectomies 
(33.3%), in 36 of the lobectomies (12.1%), and in one of the 
lesser resections (2.1%).
Almost 9% of the patients had major complications, 
of which reoperation for bleeding (n = 9), reoperation for 
empyema and/or bronchopleural fistula (n = 7), heart failure 
(n = 7), and myocardial infarction (n = 6) were the most com-
mon (Table 5). The rate of major complications was signifi-
cantly higher for the patients who underwent pneumonectomy 
(18.3%) than for those who underwent lobectomy (7.1%) and 
lesser resection (6.4%) (p = 0.01; Table 5).
Two patients died within 30 days of lobectomy and two 
others died after pneumonectomy, but there was no operative 
mortality after lesser resection. Operative mortality for the 
whole group was therefore 1.0%.
Five-year OS for the whole group was 40.7%. It was 
significantly higher for the last 5-year period than for the 
first (43.8% versus 34.8%; log-rank test, p = 0.039) (Table 1). 
Figure 1 shows OS for the different procedures. Survival at 5 
years was 44.6% after lobectomy, 40.7% after lesser resection, 
TABLE 2.  Patient Demographics and Comorbidities in Patients in Iceland, Who Underwent Surgical Resection With 
Curative Intent for NSCLC, 1994 to 2008
Lobectomy 
(n = 297)
Pneumonectomy 
(n = 60)
Lesser Resections 
(n = 47)
All Procedures 
(n = 404)
Male sex 148 (49.9) 42 (70.0) 21 (44.7) 211 (52.2)
Age, years (range) 65.9 (37–89) 62.7 (45–83) 69.1 (43–84) 65.8 (37–89)
History of smoking 285 (96.0) 59 (98.3) 46 (97.9) 390 (96.5)
COPD 73 (24.7) 14 (23.3) 19 (40.4)a 106 (26.3)
FEV1 < 75% predicted 83 (27.9) 20 (33.3) 20 (42.6) 123 (30.5)
Coronary artery disease 72 (24.2) 12 (20.0) 26 (55.3)a 110 (27.2)
ASA score, mean 2.6 2.6 2.6 2.6
The numbers of patients are given with percentages in parentheses, except for age and ASA score where means are given.
a Statistically significant difference between groups (p < 0.05).
NSCLC, non–small-cell lung cancer; COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume in 1 second; ASA, American Society of Anesthesiologists.
TABLE 3.  Tumor Histology, Disease Stage (pTNM), and Other Pathological Data for Patients in Iceland, Who Underwent 
Surgical Resections (Lobectomy, Pneumonectomy, and Lesser Resections) with Curative Intent for NSCLC, 1994 to 2008
Lobectomy 
(n = 297)
Pneumonectomy 
(n = 60)
Lesser Resections 
(n = 47)
All Procedures 
(n = 404)
Tumor histology
 Adenocarcinoma 179 (60.2) 22 (36.7)a 31 (66.0) 138 (57.4)
 Squamous-cell 85 (28.6) 32 (53.3)a 11 (23.4) 128 (31.7)
 Large-cell 19 (6.4) 3 (5.0) 1 (2.1) 23 (5.7)
 Other (including adenosquamous) 13 (4.3) 3 (5.0) 4 (8.5) 20 (5.0)
Disease stage (pTNM)
 I 179 (60.2) 8 (13.3)a 37 (78.7) 224 (55.4)
 II 59 (19.9) 27 (45.0)a 8 (17.0) 94 (23.3)
 IIIA 19 (6.4) 9 (15) 2 (4.3) 30 (7.4)
 IIIB 22 (7.4) 13 (21.7) 0 35 (8.7)
 IV 18 (6.1) 3 (5.0) 0 21 (5.2)
Mean size of tumor, mm (range) 39 (4–190) 57 (20–150) 23 (8–50) 40 (4–190)
Positive surgical margins 27 (9.1) 7 (11.7) 9 (18.8) 43 (10.6)
The numbers of patients are given with percentages in parentheses, except for tumor size where means with range are given.
a Statistically significant difference between groups (p < 0.05).
TNM, tumor, node, metastasis; NSCLC, non–small-cell lung cancer.
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and significantly lower (22.0%) after pneumonectomy (p = 
0.006). The NSCLC patients who did not undergo surgery 
had a much less favorable survival: only 4.8% after 5 years. 
Survival for all NSCLC patients together was 12.4% at 5 
years, but 46.8% for stages I and II together for the operated 
patients. Survival for the different stages is shown in Table 4 
and Figure 2.
DISCUSSION
Our results show that the SRR for NSCLC in Iceland (at 
26.4%) is higher than in other European studies, where SRR 
has usually been reported to be in the 15% to 25% range.6–9 
To the best of our knowledge, this is the first report of SRR 
for a whole nation. Short-term outcome for all procedures was 
excellent, with low rates of major complications and an opera-
tive mortality of only 1.0%; other studies have found figures 
between 1.5% and 7%.5,8,14,17–19
The rate of major complications was 8.7%, which is low 
compared to other studies. However, comparisons between 
studies can be difficult because of the different criteria used. 
In the study by Myrdal et al.14 the rate of major complications 
was 8.8%, and it was 12.4% in the study by Yano et al.15 In 
another study, the major complication rate was 13%, but the 
authors’ definition of major complications was wider than that 
in the present study.16
Five-year survival in this study was 40.7% for the 
whole study period and it improved from 34.8% during the 
first 5-year period to 43.8% for the last 5-year period (p = 
0.04). Survival figures from other studies have ranged from 
30% to 60% at 5 years,10,22–24 and from around 50% to 60% 
for patients with stage I and II disease, which are somewhat 
higher than observed for stage I and II patients in our study, 
or 47%.20
Few studies evaluating surgical outcomes of NSCLC 
have included all three types of operations. In this study, sur-
vival after lesser resection was similar to that after lobectomy, 
even though a higher proportion of patients in the lesser resec-
tion group had underlying cardiopulmonary disease. There 
was, however, a higher proportion of patients with stage I 
disease in the lesser-resection group. The low complication 
rate and low mortality rate in the lesser-resection group raises 
the question of whether some of these patients could have 
TABLE 4.  Overall 5-Year Survival According to Both the 6th 
and 7th Edition of the TNM Staging System for Patients in 
Iceland With NSCLC Who Underwent Surgical Resection With 
Curative Intent, 1994 to 2008
TNM 
Stage
6th 
Edition (n) 
Survival at 
5 Years (%)
7th 
Edition (n) 
Survival at 
5 Years (%)
I 224 55.3 194 58.1
II 94 26.6 128 29.4
IIIA 30 19.9 61 22.1
IIIB 35 23.8 3 NAa
IV 21 7.1 18 5.4
I + II 318 46.8 322 46.7
III + IV 86 18.4 82 17.8
a Only three patients, calculations therefore not available.
NA, not available.
TABLE 5.  Minor and Major Complications in Patients in Iceland Who Underwent Different Lung Operations With 
Curative Intent for NSCLC, 1994 to 2008
Lobectomy 
(n = 297)
Pneumonectomy 
(n = 60)
Lesser Resections 
(n = 47)
All Procedures 
(n = 404)
Minor complications 105 (35.4) 30 (50.0) 16 (34.0) 151 (37.4)
Intraoperative bleeding 
> 1 l
24 (8.1) 20 (33.3)a 0 (0) 44 (10.9)
Atrial fibrillation/flutter 18 (6.1) 15 (25.0)a 1 (2.1) 34 (8.4)
Recurrent laryngeal 
nerve paralysis
5 (1.7) 2 (3.3) 0 (0) 7 (1.7)
Air leakage for > 7 days 63 (21.2) 1 (1.7) 6 (12.8) 70 (17.3)
Pneumonia 16 (5.4) 3 (5.0) 7 (14.9)a 26 (6.4)
Wound infection 5 (1.7) 1 (1.7) 2 (4.3) 8 (2.0)
Major complications 21 (7.1) 11 (18.3)a 3 (6.4) 35 (8.7)
ARDS 6 (2.0) 3 (5.0) 0 9 (2.2)
Reoperation for 
bleeding
6 (2.0) 3 (5.0) 0 9 (2.2)
Reoperation for 
empyema and/or BPF
3 (1.0) 4 (6.7) 0 7 (1.7)
Heart failure 6 (2.0) 0 1 (2.1) 7 (1.7)
Myocardial infarction 4 (1.3) 1 (1.7) 1 (2.1) 6 (1.5)
Empyema 3 (1.0) 3 (5.0) 0 6 (1.5)
Bronchopleural fistula 1 (0.3) 1 (1.7) 0 2 (0.5)
Stroke 0 0 1 (2.1) 1 (0.2)
A patient could have more than one complication. The numbers of patients are given with percentages in parentheses.
a Statistically significant difference between groups (p < 0.05).
NSCLC, non–small-cell lung cancer; ARDS, acute respiratory distress syndrome; BPF, bronchopleural fistula.
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tolerated a lobectomy. Alternatively, this could also be an 
argument for greater use of lesser resections in patients with 
small tumors. This question is being actively studied, as there 
is growing evidence that lesser resections are a reasonable 
approach for small peripheral tumors (of < 2 cm) and also for 
small ground-glass opacity lesions detected by CT imaging.25
As expected, survival after pneumonectomy was signifi-
cantly lower than after lobectomy and lesser resection. Our 
result of 22% 5-year survival after pneumonectomy seems 
disproportionately low when compared to the results of other 
studies that have shown rates from 27% to 40%.26–29 The reason 
for the low survival after pneumonectomy is open to debate, 
but understaging because of a low rate of mediastinoscopies 
may have had a role. Tumors requiring pneumonectomy are 
often large and centrally located, and spread more often to the 
mediastinal lymph nodes, making mediastinoscopy even more 
important in the workup of these patients.30 The use of PET 
scans, which was not available for this patient population, is 
also known to improve preoperative staging and to prevent 
unnecessary surgery.
As shown in Table 1, it is unlikely that stage distri-
bution explains improved survival, as it did not change sig-
nificantly during the study period. A number of advances 
have been made in the preoperative evaluation and staging 
of patients with NSCLC in recent years. Improvements in 
imaging techniques and increased use of mediastinoscopy 
may have resulted in more patients being excluded from 
surgical resection because of advanced disease. This could 
have contributed to the fact that survival improved during 
the last 5-year period of this study. Improvements in surgi-
cal techniques, with increases in the number of cases oper-
ated on per surgeon, are also known to play a role.24 Finally, 
more frequent use of adjuvant chemotherapy for stage II dis-
ease during the last period might also have contributed to 
improved survival.31
This is a retrospective study with the potential bias that 
it can introduce, problems like lack of a complete preopera-
tive stage and documentation of complications. Furthermore, 
PET scan was not available in Iceland for staging, and medi-
astinoscopy was used routinely for mediastinal staging dur-
ing the last 5 years of the study. The strength of this study is 
that our cohort consisted of patients from a whole popula-
tion, all of whom were operated on in a single center. The 
results were therefore less likely to be affected by tertiary 
referral.
We have reported resection rate, rates of complications, 
and survival rates for all patients who underwent surgery with 
curative intent for NSCLC in the Icelandic population during 
a 15-year period. In our opinion, these data should be reported 
together in context to help evaluate the outcome of surgical 
care for patients with NSCLC. Furthermore, we have reported 
survival of patients with NSCLC who were not operated on, 
which is important for comparison.
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